Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and Safety of Symbravo® (MoSEIC(TM) Meloxicam and Rizatriptan) in Participants with Migraine Previously Treated with Oral CGRP Inhibitors: Topline Results from the EMERGE Trial

Efficacy of Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) by Baseline Migraine-associated Disability: Post-hoc Analysis of the INTERCEPT Trial 

Long-term Effects of Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) on Headache Burden and Quality of Life: Results of the MOVEMENT Trial